TGA releases defective batch to combat EpiPen Jr shortage

It says the risk of anaphylaxis outweighs other risks

The TGA has agreed to release a batch of EpiPen Jr that did meet not all quality requirements in an attempt to reduce the impact of the critical shortage of the adrenaline auto-injector.